QQ客服 官方微博 反馈留言

浏览/检索结果: 共17条，第1-10条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择发表日期升序发表日期降序提交时间升序提交时间降序题名升序题名降序作者升序作者降序 程序性死亡蛋白1抗体SHR-1210治疗晚期实体瘤患者中肾上腺皮质功能减退的临床报道 期刊论文 2019, 卷号: 41, 期号: 6, 页码: 466-470 作者:  汤佳琳;  黄镜;  王玺;  陈雪莲;  李群 收藏  |  浏览/下载：8/0  |  提交时间：2020/01/03 实体肿瘤  SHR-1210  程序性死亡蛋白1抗体  继发性肾上腺皮质功能减退  垂体炎   Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China 期刊论文 2019, 卷号: 125, 期号: 5, 页码: 742-749 作者:  Huang, Jing;  Mo, Hongnan;  Zhang, Weilong;  Chen, Xuelian;  Qu, Dong 收藏  |  浏览/下载：21/0  |  提交时间：2020/01/03 B7-H1 antigen  DNA mismatch repair  l-lactate dehydrogenase  programmed cell death 1 receptor  stomach neoplasms   Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody 期刊论文 2019, 卷号: 10, 期号: 6, 页码: 1395-1401 作者:  Wang, Xi;  Zhang, Bo;  Chen, Xuelian;  Mo, Hongnan;  Wu, Dawei 收藏  |  浏览/下载：3/0  |  提交时间：2020/01/03 Esophageal squamous cell carcinoma  immune checkpoint inhibitor  lactate dehydrogenase  markers  programmed cell death-1   Reactive capillary hemangiomas induced by camrelizumab (SHR-1210), an anti-PD-1 agent 期刊论文 2019, 卷号: 58, 期号: 3, 页码: 388-389 作者:  Teng, Yan;  Guo, Ruifeng;  Sun, Jianfang;  Jiang, Yiqun;  Liu, Yi 收藏  |  浏览/下载：6/0  |  提交时间：2020/01/03 Reactive capillary hemangiomas: a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210 期刊论文 2019, 卷号: 16, 期号: 1, 页码: 173-+ 作者:  Chen, Xuelian;  Ma, Lanying;  Wang, Xi;  Mo, Hongnan;  Wu, Dawei 收藏  |  浏览/下载：7/0  |  提交时间：2020/01/03 Reactive capillary hemangiomas  SHR-1210  skin toxicity  anti-tumor efficacy   A randomized multicentered phase II study to evaluate SHR-1210 (PD-1 antibody) in subjects with advanced hepatocellular carcinoma (HCC) who failed or intolerable to prior systemic treatment 会议论文 作者:  Qin, S. K.;  Ren, Z. G.;  Meng, Z. Q.;  Chen, Z. D.;  Chai, X. L. 收藏  |  浏览/下载：6/0  |  提交时间：2019/12/05 A randomized multicentered phase II study to evaluate SHR-1210 (PD-1 antibody) in subjects with advanced hepatocellular carcinoma (HCC) who failed or intolerable to prior systemic treatment 会议论文 作者:  Qin, S. K.;  Ren, Z. G.;  Meng, Z. Q.;  Chen, Z. D.;  Chai, X. L. 收藏  |  浏览/下载：3/0  |  提交时间：2019/11/19 Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials 期刊论文 LANCET ONCOLOGY, 2018, 卷号: Vol.19 No.10, 页码: 1338-1350 作者:  Fang, Wenfeng;  Yang, Yunpeng;  Ma, Yuxiang;  Hong, Shaodong;  Lin, Lizhu 收藏  |  浏览/下载：10/0  |  提交时间：2019/02/25 Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials 期刊论文 2018, 卷号: 19, 期号: 10, 页码: 1338-1350 作者:  Fang, Wenfeng;  Yang, Yunpeng;  Ma, Yuxiang;  Hong, Shaodong;  Lin, Lizhu 收藏  |  浏览/下载：7/0  |  提交时间：2020/01/03 程序性死亡蛋白1抗体SHR-1210治疗晚期实体瘤的甲状腺功能相关不良反应 期刊论文 2018, 卷号: 40, 期号: 10, 页码: 772-775 作者:  祁玲;  莫红楠;  陈雪莲;  王玺;  吴大维 收藏  |  浏览/下载：2/0  |  提交时间：2020/01/03 肿瘤  PD-1抗体  甲状腺  不良反应  免疫治疗